Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

T. Yoshino, DC. Portnoy, R. Obermannová, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. García-Alfonso, AL. Cohn, E. Van Cutsem, K. Yamazaki, S. Lonardi, K. Muro, TW. Kim, K. Yamaguchi, A. Grothey, J. O'Connor, J. Taieb, SR....

. 2019 ; 30 (1) : 124-131. [pub] 20190101

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006752

Background: : Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73-0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods: Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results: RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR = 0.86, 95% CI 0.71-1.04) and patients with RAS/BRAF wild-type tumours (OS HR = 0.86, 95% CI 0.64-1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR = 0.54, 95% CI 0.25-1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P = 0.523, PFS P = 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR = 0.81, 95% CI 0.68-0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR = 0.97, 95% CI 0.75-1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P = 0.276). Conclusions: In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant. ClinicalTrials.gov number: NCT01183780.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006752
003      
CZ-PrNML
005      
20200526084953.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdy461 $2 doi
035    __
$a (PubMed)30339194
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Yoshino, T $u National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp.
245    10
$a Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / $c T. Yoshino, DC. Portnoy, R. Obermannová, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. García-Alfonso, AL. Cohn, E. Van Cutsem, K. Yamazaki, S. Lonardi, K. Muro, TW. Kim, K. Yamaguchi, A. Grothey, J. O'Connor, J. Taieb, SR. Wijayawardana, RR. Hozak, F. Nasroulah, J. Tabernero,
520    9_
$a Background: : Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73-0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods: Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results: RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR = 0.86, 95% CI 0.71-1.04) and patients with RAS/BRAF wild-type tumours (OS HR = 0.86, 95% CI 0.64-1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR = 0.54, 95% CI 0.25-1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P = 0.523, PFS P = 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR = 0.81, 95% CI 0.68-0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR = 0.97, 95% CI 0.75-1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P = 0.276). Conclusions: In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant. ClinicalTrials.gov number: NCT01183780.
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a kamptothecin $x aplikace a dávkování $7 D002166
650    _2
$a cetuximab $x aplikace a dávkování $7 D000068818
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x aplikace a dávkování $7 D005472
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a leukovorin $x aplikace a dávkování $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a metastázy nádorů $7 D009362
650    12
$a patologická angiogeneze $7 D009389
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-raf $x genetika $7 D019908
650    _2
$a míra přežití $7 D015996
650    _2
$a ras proteiny $x genetika $7 D018631
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Portnoy, D C $u The West Clinic, Memphis, USA.
700    1_
$a Obermannová, R $u Masarykuv Onkologicky Ustav, Brno, Czech Republic.
700    1_
$a Bodoky, G $u St. Laszlo Hospital, Budapest, Hungary.
700    1_
$a Prausová, J $u Fakultni Nemocnice v MOTOLE, Prague, Czech Republic.
700    1_
$a Garcia-Carbonero, R $u Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain.
700    1_
$a Ciuleanu, T $u Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
700    1_
$a García-Alfonso, P $u Hospital General Univ Gregorio Marañón, Madrid, Spain.
700    1_
$a Cohn, A L $u Rocky Mountain Cancer Center, LLP, Denver, USA.
700    1_
$a Van Cutsem, E $u Univ Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
700    1_
$a Yamazaki, K $u Shizuoka Cancer Center, Shizuoka, Japan.
700    1_
$a Lonardi, S $u Istituto Oncologico Veneto-IRCCS, Padova, Italy.
700    1_
$a Muro, K $u Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
700    1_
$a Kim, T W $u Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
700    1_
$a Yamaguchi, K $u The Cancer Institute Hospital of JFCR, Tokyo, Japan.
700    1_
$a Grothey, A $u Mayo Clinic, Phoenix, USA.
700    1_
$a O'Connor, J $u Instituto Alexander Fleming, Buenos Aires, Argentina.
700    1_
$a Taieb, J $u Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France.
700    1_
$a Wijayawardana, S R $u Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Hozak, R R $u Eli Lilly and Company, Indianapolis, USA.
700    1_
$a Nasroulah, F $u Eli Lilly and Company, Buenos Aires, Argentina.
700    1_
$a Tabernero, J $u Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
773    0_
$w MED00000432 $t Annals of oncology : official journal of the European Society for Medical Oncology $x 1569-8041 $g Roč. 30, č. 1 (2019), s. 124-131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30339194 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526084949 $b ABA008
999    __
$a ok $b bmc $g 1525610 $s 1096808
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 30 $c 1 $d 124-131 $e 20190101 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace